G. Andriole

Publications762
h-index88
Citations36,633
Highly Influential Citations1,168
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • S. Freedland
  • 1,029 Publications • 22,518 Citations
  • S. Chanock
  • 964 Publications • 59,686 Citations
  • P. Walsh
  • 1,013 Publications • 79,181 Citations
  • I. Thompson
  • 585 Publications • 31,971 Citations
  • Publications
  • Influence
Mortality results from a randomized prostate-cancer screening trial.
BACKGROUND The effect of screening with prostate-specific-antigen (PSA) testing and digital rectal examination on the rate of death from prostate cancer is unknown. This is the first report from the… Expand
  • 2,630
  • 97
  • PDF
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
BACKGROUND Benign prostatic hyperplasia is commonly treated with alpha-adrenergic-receptor antagonists (alpha-blockers) or 5alpha-reductase inhibitors. The long-term effect of these drugs, singly or… Expand
  • 1,615
  • 74
  • PDF
Measurement of prostate-specific antigen in serum as a screening test for prostate cancer.
BACKGROUND Prostate-specific antigen (PSA) is secreted exclusively by prostatic epithelial cells, and its serum concentration is increased in men with prostatic disease, including cancer. We… Expand
  • 2,147
  • 57
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24
Recently, common variants on human chromosome 8q24 were found to be associated with prostate cancer risk. While conducting a genome-wide association study in the Cancer Genetic Markers of… Expand
  • 1,095
  • 45
  • PDF
Effect of dutasteride on the risk of prostate cancer.
BACKGROUND We conducted a study to determine whether dutasteride reduces the risk of incident prostate cancer, as detected on biopsy, among men who are at increased risk for the disease. METHODS In… Expand
  • 942
  • 38
  • PDF
Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
The objectives of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial are to determine in screenees ages 55-74 at entry whether screening with flexible sigmoidoscopy (60-cm… Expand
  • 805
  • 36
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.
BACKGROUND The prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial was undertaken to determine whether there is a reduction in prostate cancer mortality… Expand
  • 942
  • 36
  • PDF
Multiple loci identified in a genome-wide association study of prostate cancer
We followed our initial genome-wide association study (GWAS) of 527,869 SNPs on 1,172 individuals with prostate cancer and 1,157 controls of European origin—nested in the Prostate, Lung, Colorectal,… Expand
  • 924
  • 34
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.
CONTEXT Screening for ovarian cancer with cancer antigen 125 (CA-125) and transvaginal ultrasound has an unknown effect on mortality. OBJECTIVE To evaluate the effect of screening for ovarian… Expand
  • 718
  • 30
  • PDF
Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.
OBJECTIVES To study the efficacy and safety of dutasteride, a dual inhibitor of the 5-alpha-reductase isoenzymes types I and II. METHODS A total of 4325 men (2951 completed) with clinical benign… Expand
  • 638
  • 29
...
1
2
3
4
5
...